Product image of Mirtazapin Ratiopharm® (Mirtazapine) supplied by GNH India

Mirtazapin Ratiopharm®

Active Ingredient:
Mirtazapine
Origin:
EU

Mirtazapin Ratiopharm® (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Ratiopharm®, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral, buccal and sublingual use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH India supplies Mirtazapin Ratiopharm® as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ratiopharm Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirtazapin Ratiopharm® acts within the antidepressant drug class to address mood disorders.

  • Major depressive disorder: reduces depressive symptoms and improves mood in adults.
  • Treatment‑resistant depression: may be considered when first‑line agents are insufficient.
  • Adjunctive therapy for bipolar depressive episodes: can be used under specialist supervision to manage depressive phases.

How It Works

  • Mirtazapine blocks central presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes postsynaptic 5‑HT2, 5‑HT3 and histamine H1 receptors. This combined action enhances noradrenergic and serotonergic neurotransmission while producing sedative effects, contributing to its antidepressant efficacy.

Side Effects

Mirtazapin Ratiopharm® may cause a range of adverse reactions.

Common Side Effects

  • Sedation or drowsiness
  • Increased appetite and weight gain
  • Dry mouth
  • Constipation
  • Dizziness
  • Peripheral edema

Serious or Rare Side Effects

  • Agranulocytosis or severe neutropenia
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis
  • Severe hypersensitivity reactions including anaphylaxis
  • Suicidal thoughts or behavior, especially early in treatment
  • Hepatic dysfunction or jaundice

Precautions & Warnings

Before prescribing Mirtazapin Ratiopharm®, clinicians should consider several safety aspects.

  • Monitor weight: patients often experience increased appetite and weight gain.
  • Assess for suicidal ideation: watch for emergence of suicidal thoughts, particularly in early treatment.
  • Evaluate hepatic function: use caution in patients with liver impairment.
  • Review concomitant CNS depressants: combined use may enhance sedation.
  • Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms.
  • Store at room temperature (below 25°C): keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Mirtazapin Ratiopharm® can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
  • Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome.
  • CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.
  • Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine plasma levels.

Moderate Interactions (Monitor Closely)

  • Antihypertensives: possible additive hypotensive effect.
  • Anticholinergic drugs: heightened anticholinergic burden.
  • Carbamazepine or phenytoin: may reduce mirtazapine concentrations.
  • Warfarin: monitor INR for possible alteration of anticoagulation.
  • Lithium: observe for increased central nervous system effects.

Frequently Asked Questions

Mirtazapin Ratiopharm® contains mirtazapine, a NaSSA‑type antidepressant indicated for the treatment of major depressive disorder in adult patients. It may also be employed in treatment‑resistant depression or as adjunctive therapy for depressive phases of bipolar disorder under specialist guidance.

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes postsynaptic 5‑HT2, 5‑HT3 and histamine H1 receptors. This dual action enhances noradrenergic and serotonergic signaling while providing a sedative effect, together contributing to mood improvement.

The appropriate dose of Mirtazapin Ratiopharm® is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in stronger sedative and appetite‑stimulating effects. This can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapin Ratiopharm® should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability.

The medication is taken orally, typically as a tablet. It can be swallowed whole with water and may be administered with or without food, according to the prescriber’s instructions.

Serious risks include the potential for agranulocytosis or severe neutropenia, hypersensitivity reactions such as Stevens‑Johnson syndrome, and the emergence of suicidal thoughts, especially early in treatment. Prompt medical attention is required if any of these events occur.

Patients with known hypersensitivity to mirtazapine or any of its excipients, those currently on monoamine oxidase inhibitors, or individuals with severe hepatic impairment should avoid using Mirtazapin Ratiopharm® unless specifically directed by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirtazapine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT